Antitrust considerations now a much bigger factor in pharma patent dealmaking
Following recent forced divestments - and with growing political concern about life sciences acquisitions - the signs are that regulators will play a larger role in transactions
To read more
Register for limited access
Register to receive our newsletter and gain limited access to subscriber content.
Subscribe to unlock unlimited access
Get news, unique commentary, expert analysis and essential resources from the IAM experts.